XBI: Surprise Exit Of A Tough Regulator At The FDA

Core Insights - The SPDR S&P Biotech ETF (NYSEARCA: XBI) has increased over 20% from its lows in early April, despite indications of a more challenging regulatory environment from the US Food and Drug Administration (FDA) [1] Group 1 - The ETF's performance suggests resilience in the biotech sector, even amid regulatory concerns [1] - The focus of trading is on events such as trial results and NDA/BLA approvals, indicating a strategy centered around significant industry milestones [1]